Overview
To assess the tolerability, safety, and pharmacokinetics (PK) of ONO-7913 in patients with advanced or metastatic solid cancers and explore its efficacy and biomarkers.
Eligibility
Inclusion Criteria:
- Patients with histologically or cytologically confirmed advanced or metastatic solid tumors
- ECOG Performance Status of 0-1
- Patients with life expectancy of at least 3 months
Exclusion Criteria:
- Patients with multiple cancers
- Patients with history of serious allergy